Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322037 | 0.88 | HSD11B1 (0.69) | HSD11B1KDM4EEPHX2MAPK1ALDH1A1 | |
| SCHEMBL13949937 | 0.85 | HSD11B1 (0.54) | HSD11B1KDM4EEPHX2MAPK1ALDH1A1 | |
| SCHEMBL3327946 | 0.82 | HSD11B1 (1.00) | HSD11B1KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL3327631 | 0.80 | HSD11B1 (0.67) | HSD11B1KDM4EALDH1A1KMT2APOLB | |
| SCHEMBL15009750 | 0.79 | KDM4E (0.59) | HSD11B1KDM4EALDH1A1GLAKMT2A | |
| SCHEMBL3323134 | 0.78 | KDM4E (0.59) | HSD11B1KDM4EEPHX2MAPK1ALDH1A1 | |
| SCHEMBL3321023 | 0.78 | HSD11B1 (0.74) | HSD11B1KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL14142610 | 0.78 | LMNA (0.80) | HSD11B1KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL3320923 | 0.76 | KDM4E (0.57) | HSD11B1KDM4EEPHX2ALDH1A1GLA | |
| SCHEMBL13361608 | 0.76 | HSD11B1 (0.87) | HSD11B1KDM4EALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399475-B2 | Crystalline and amorphous forms of naltrexone hydrochloride | MALLINCKRODT LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120814-A1 | Crystalline and Amorphous Forms of Naltrexone Hydrochloride | OCERA THERAPEUTICS LLC | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120814-A1 | Crystalline and Amorphous Forms of Naltrexone Hydrochloride | SLC6A3, OPRK1, LPXN | HSD11B1 612/4885KDM4E 1425/4885EPHX2 2752/4885 |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885KDM4E 1839/4885EPHX2 481/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | HSD11B1 73/4885KDM4E 1594/4885EPHX2 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.